Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin for stable bronchiectasis colonized by Pseudomonas aeruginosa
ChiCTR2200066125Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carrimycin in bronchiectasis (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Bacteriological changes in sputum from baseline to day 7. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
carrimycin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ChiCTR2200066125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066125.